Disease Focus
Galvanize is developing technologies to treat several conditions.
Menu
Menu
Galvanize Therapeutics, Inc.
3200 Bridge Parkway
Redwood City, CA 94065
© 2024 Galvanize Therapeutics, Inc. All rights reserved.
©
2024
Galvanize Therapeutics, Inc.
All rights reserved.
Steve is Chief Financial Officer at Galvanize. He brings a proven history of driving growth in revenue and profitability. Most recently, Steve was CFO of Vocera Communications, a publicly traded healthcare IT company focused on clinical communication and collaboration, which was acquired by Stryker Corporation for $3.1 billion. Steve was internally promoted into the CFO position at Vocera from his role as Vice President of Finance & Accounting. Prior to Vocera, Steve served in various roles of increasing responsibility for Accuray Incorporated in Strategic Finance and Investor Relations. He started his career at KPMG where he received his CPA and holds a bachelor’s degree in accounting from California Polytechnic State University San Luis Obispo.
Senior Vice President, Sales and Marketing, Electrophysiology
Michael is senior vice president of Sales and Marketing, Electrophysiology. He brings to Galvanize more than 20 years of commercial experience in the Electrophysiology market. He most recently served as Chief Commercial Officer at Acutus Medical and previously worked in various leadership positions at Biotronik, Boston Scientific and Guidant. He holds an MBA from the University of Michigan and a bachelor’s degree in Economics from Copenhagen Business School.
Founder and Managing Partner, ATP
Seth Harrison is founder and managing partner of ATP (Apple Tree Partners), a leading life sciences venture capital firm. Seth began investing in life sciences in 1991 as a venture partner at Sevin Rosen Funds and went on to be a general partner at Oak Investment Partners before starting ATP in 1999. Some of his earlier investments include Aileron Therapeutics, Akero Therapeutics, ArQule, Chinook Therapeutics, Coelacanth, Corvidia Therapeutics, Cyrano Sciences, Gloucester Pharmaceuticals, HeartWare, Informed Access, SGX Pharmaceuticals, Stoke Therapeutics, Syntimmune, Tendyne, Ultracision, and ViroPharma. Seth currently serves on the boards of Akero Therapeutics and Stoke Therapeutics as well as the boards of the 15 portfolio companies created within ATP’s current fund to date. From 2002 to 2010, he was a member of the board of the International Partnership for Microbicides, a nonprofit product development partnership focused on women’s health and HIV prevention. Seth received an AB from Princeton University and an MD and MBA both from Columbia University, and completed a surgery internship at the Presbyterian Hospital in the City of New York.
Anna Batarina is a partner at ATP (Apple Tree Partners), a leading life sciences venture capital firm. She joined ATP in 2016 from Braeburn, an ATP portfolio company, where she served as vice president of Strategic Development. Before Braeburn, she was a member of the strategy team at the Global Fund to Fight AIDS, Tuberculosis and Malaria. Prior to that, she was senior vice president and head of Capital Markets and Investor Relations at Uralkali, a leading global agrochemical business, where she led one of the most successful IPOs on the London Stock Exchange. Anna received an MA in Global Affairs (Global Health track) and a graduate certificate in Global Health, Public Health from Yale University. She holds an MS in clinical psychology from Lomonosov Moscow State University, a BS in finance from Financial University under the Government of the Russian Federation, and a CFA charter.
Executive Chairman, Galvanize
Doug Godshall, executive chairman of Galvanize, was president and CEO of Shockwave Medical until its sale to Johnson & Johnson in 2024 for $13.1B. He is the former CEO and Director of HeartWare, an innovator in LVAD acquired by Medtronic in 2016 for $1.1B. Prior to HeartWare, Doug held executive and leadership positions at Boston Scientific, including president of the Vascular Surgery Division, member of the Operating Committee and vice president of Business Development. Doug also serves on the Board of Saluda Medical and served on the board of Gala Therapeutics before it merged into Galvanize Therapeutics. He earned an MBA from Northeastern University and a BA in Economics from Lafayette College.
Michael is Vice President of Business Development and Commercial Strategy. He brings to Galvanize more than 20 years of commercial experience in the Electrophysiology market. He most recently served as Chief Commercial Officer at Acutus Medical and previously worked in various leadership positions at Biotronik, Boston Scientific and Guidant. He holds an MBA from the University of Michigan and a bachelor’s degree in Economics from Copenhagen Business School.
Senior Vice President, Sales and Marketing
Bill serves as senior vice president of Sales and Marketing for Galvanize. Bill has been a part of the Thoracic Oncology and Interventional Oncology space since 2004. He has led early commercial teams at medical device startups, such as superDimension (acquired by Covidien/Medtronic in 2012), NeuWave Medical (acquired by Johnson & Johnson in 2015), and most recently at Auris Health, where he was the vice president of Sales. Auris was acquired by Johnson & Johnson for $3.4 billion in 2019, one of the largest pre-IPO medical device company acquisitions to date. Bill has a bachelor’s degree in Business Finance from Duquesne University.
Chief Medical Officer
William Krimsky is Chief Medical Officer of Galvanize. Bill has been a pioneer in the Interventional Pulmonology space for more than 20 years, carving an innovative pathway for the treatment of lung diseases. In 2015, he co-invented the RheOx technology with Jonathan Waldstreicher to continue his focus on therapeutic intervention in the pulmonary and oncology field. Bill earned his medical degree at the University of Pittsburgh School of Medicine and completed an internship at Mercy Hospital and a residency at Johns Hopkins University/Sinai Hospital. Following that, he was a fellow in pulmonary and critical care medicine at Dartmouth-Hitchcock Medical Center and a visiting fellow in Interventional Pulmonology at the Hospital of the University of Pennsylvania. He is the author of multiple publications.
Chief Regulatory Officer
Deborah Sheffield is Chief Regulatory Officer at Galvanize. She is an experienced professional in the design and development of innovative products, with over 25 years of experience in and understanding of the global regulatory environment in the medical device field. She has successfully obtained US and International medical device approvals for clinical studies and market clearance/approvals for Class I, II and III devices in markets including US, Canada, Australia, South America, India and Europe. Her technology experience encompasses a variety of medical devices platforms, including energy-based therapies (RF, laser, ultrasound, IRE), active implantables, and IVD devices for disease states including neuro, pulmonary, GI and cardiac functions.
Deb has previously held several key leadership positions at companies including Johnson & Johnson and at several start-up companies including Northstar Neuroscience (IPO and subsequently acquired by St. Jude Medical). She holds a BS from Kettering University in Industrial Manufacturing Engineering and a MS from Oakland University in Applied Statistics. She also attended the University of Cincinnati Nursing School with a focus on clinical research.
Jonathan is founder and CEO of Galvanize. He has worked in medical devices as an entrepreneur, investor, and clinician. Jon was previously a partner on the MedTech team at ATP, the life sciences venture capital firm where he founded Gala Therapeutics in 2015 and Galaxy Medical in 2020, both of which were merged into Galvanize in 2022. Prior to joining ATP, Jon was a director of Global Surgery R&D at Johnson &
Johnson. He started at J&J as an associate director in the Corporate Office of Science & Technology. Before medical school, Jon worked in equity research at Bear Stearns. Jon received a BA from Brandeis University in economics and an MD and MBA from Tufts University School of Medicine. He completed a general surgery internship at Tufts
Medical Center in Boston.
